Tallarna and ABB Strengthen Strategic Partnership With Investment Deal
22.11.2022 14:00:00 EET | Business Wire | Press release
Tallarna, an award-winning climate tech company for the built environment, today announced that it has closed a strategic partnership and minority investment deal with ABB, a technology leader in electrification and automation. This signals a joint commitment to a software-led, risk-managed approach to accelerate net zero.
ABB’s solutions connect engineering know-how and software to optimise how things are manufactured, moved, powered, and operated. Building on more than 130 years of excellence, the company's expertise will be indispensable for the next stage of Tallarna’s growth.
Since launching four years ago, Tallarna has built a talented and loyal team, and has experienced wide-scale traction across the real estate sector – encompassing social housing providers, energy infrastructure developers, and green lenders. With ABB’s backing, the company’s scope will be extended to Energy Service Companies (ESCOs) serving commercial and industrial organisations.
Tallarna’s AI platform, KESTREL, makes decarbonisation projects a reality by aligning what can be achieved from an engineering perspective with what can be insured and funded. By finding the commonality between decision makers, the company opens the door to a new era of scalability. Tallarna’s software is integrated with the related underwriting processes of AmTrust Financial Services, a global specialty property and casualty insurer, who is also an existing investor. Together, the companies have created a unique Energy Savings Insurance product which enables customers to access project investors integrated into Tallarna’s platform.
As the climate and energy crisis grows, decision makers need the right tools to lower their emissions and operating costs. ABB’s deep knowledge of equipment performance and innovative electrification technology will enhance Tallarna’s existing capabilities. Coupling ABB products with performance insurance will give customers the confidence to action their sustainability journey.
“Never before has there been such a need for clear insights into decarbonisation possibilities and how to deliver them. Cross-industry collaboration is key to ensuring a sustainable future for all. As such, we are delighted to be working more closely with the Tallarna team and to support their launch in the ESCO market,” Giuseppe Casagrande, Global Digital Leader at ABB Electrification, Smart Power Division.
“As a company, our mission is to empower sustainability in all its forms – environmental, economic, and social. ABB shares this perspective, and we are excited to work with them on addressing the awareness, confidence, and execution gap facing customers,” Tim Meanock, CEO at Tallarna.
ABB’s investment and partnership will guide Tallarna in growing the market - taking decarbonisation to new heights for commercial, industrial, and energy infrastructure providers.
ESCO customers will benefit in 4 key ways:
-
Lower the barrier to entry for decarbonisation projects
Tallarna understands customers’ decarbonisation options using minimal data and, initially, without the need for connected devices. This capability will be augmented with ABB’s knowledge of innovative energy optimisation solutions in industrial settings.
-
Point a route to scale for customer projects
KESTREL translates engineering challenges into risk metrics and is used to underwrite and distribute Energy Savings Insurance. By adding ABB’s insights to this modelling, the companies will further mitigate risk while lowering costs and carbon emissions. Removing the performance risk from ESCOs and building owners encourages greater project scope and facilitates a service model, driving a route to scale.
-
Enable the market to move faster by overcoming barriers to execution
Guaranteed energy outputs can be financed, with the realised bill savings repaying the project costs. Not only does this deliver new funding sources for developers, but it creates financial assets for Tallarna’s panel of project investors. This provides a key mechanism for execution.
-
Ensure security of technology supply and performance
Tallarna can specify suitable technology products at the project exploration stage. These include offerings from a range of providers, including ABB. Technology is pre-validated for insurance and finance terms, and can be onboarded to provide security of supply, performance, and pricing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005392/en/
Contact information
Michelle Taute
Senior Strategic Sustainability Lead
press@tallarna.com
+44 7771786102
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
